Cargando…

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease

BACKGROUND: Current options for Chagas’ disease treatment are restricted to benznidazole and nifurtimox. To the best of our knowledge, no study has ever compared their tolerance in adults in a non-endemic country. OBJECTIVES: To compare the completion rates and drug tolerance in a cohort of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Yves, Wyssa, Baptiste, Chappuis, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021088/ https://www.ncbi.nlm.nih.gov/pubmed/31754690 http://dx.doi.org/10.1093/jac/dkz473

Ejemplares similares

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment
por: Santamaria, Cynthia, et al.
Publicado: (2014)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
por: Vázquez, Cristina, et al.
Publicado: (2023)

Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009)

Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox
por: Vergara, Camilo, et al.
Publicado: (2019)

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
por: Olivera, Mario Javier, et al.
Publicado: (2015)

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina
por: Vizcaya, David, et al.
Publicado: (2021)

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016)

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease
por: Frade, Virgínia Paula, et al.
Publicado: (2022)

Sensibilidad in vitro a benznidazol, nifurtimox y posaconazol de cepas de Trypanosoma cruzi de Paraguay
por: Acosta, Nidia, et al.
Publicado: (2020)

Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil
por: Ferreira, Ariela Mota, et al.
Publicado: (2016)

Hepatic changes by benznidazole in a specific treatment for Chagas disease
por: Pavan, Tycha Bianca Sabaini, et al.
Publicado: (2018)

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
por: Olivera, Mario J., et al.
Publicado: (2017)

Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults
por: Falk, N., et al.
Publicado: (2022)

Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017)

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
por: Gomes, Daniele Cavalcante, et al.
Publicado: (2023)

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020)

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis
por: Crespillo-Andújar, Clara, et al.
Publicado: (2022)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
por: Gontijo, Maria Katarine Costa Lucas, et al.
Publicado: (2020)

Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland
por: Jackson, Yves, et al.
Publicado: (2018)

Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs
por: Cunha, Eleonora Lima Alves, et al.
Publicado: (2019)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease
por: Fragata-Filho, Abilio Augusto, et al.
Publicado: (2016)

Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis
por: Ciapponi, Agustín, et al.
Publicado: (2020)

Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease
por: Francisco, Amanda Fortes, et al.
Publicado: (2018)

Ruthenium Complex with Benznidazole and Nitric Oxide as a New Candidate for the Treatment of Chagas Disease
por: Sesti-Costa, Renata, et al.
Publicado: (2014)

Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease
por: Rial, Marcela S., et al.
Publicado: (2017)

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study
por: Cardoso, Clareci Silva, et al.
Publicado: (2018)

Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
por: Muñoz, Gabriela, et al.
Publicado: (2019)

Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole
por: Castro Eiro, Melisa D., et al.
Publicado: (2022)

In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV
por: Revollo, Susana, et al.
Publicado: (2019)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018)

Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study
por: Hasslocher-Moreno, Alejandro M., et al.
Publicado: (2020)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rnnfkrbreocug1jjgctqkimkd6